Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchll-37gastric cancernf-kbil-6

LL-37 curbs gastric cancer angiogenesis via NF-κB/IL-6 signaling

Preclinical study reports the cathelicidin peptide inhibits tumor cell migration and vessel formation through NF-κB/IL-6 suppression.

PR
By Priya Raman · Science Reporter
Sep 15 20:00 ETSource: Histology and histopathology

The wire

  1. 01Researchers report LL-37 inhibited angiogenesis and migration in gastric cancer models via NF-κB/IL-6 inhibition.
  2. 02Adds a possible anticancer mechanism to the antimicrobial peptide LL-37.
  3. 03No clinical data; translation to patients remains untested.

From the source

Cathelicidin LL-37 inhibits angiogenesis and migration in gastric cancer via inhibition of NF-κB/IL-6 signaling

Histology and histopathology · 2026 Sep 16 · Luo H, Li S, Du H et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42745581/